Sign in to edit your profile (add interests, mentoring, photo, etc.)

    Louis VanderMolen, MD

    TitleProfessor of Clinical Medicine
    SchoolKeck School of Medicine of USC
    AddressNOR 1441 Eastlake Ave
    Health Sciences Campus
    Los Angeles California 90033
    vCardDownload vCard

      Collapse Overview 
      Collapse Overview
      Dr. VanderMolen earned his medical degree from Loyola University Stritch School of Medicine. He performed his Internal Medicine Internship and Residency from Baylor College of Medicine- Texas Medical Center. He then went on to complete two fellowships, the first in hematology at Baylor, and the second in oncology at National Cancer Institute- Clinical Oncology Program.

      Collapse Biography 
      Collapse Awards and Honors
      Phi Beta Kappa1977Elected Member
      Baylor College of Medicine1983  - 1984Chief Resident, Internal Medicine
      Orange County Medical Association2006  - 2013Physician of Excellence Award

      Collapse Bibliographic 
      Collapse Publications
      Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
      List All   |   Timeline
      1. Dillman RO, Barth NM, VanderMolen L, Mahdavi K, McClure SE. Should high-dose interleukin-2 still be the preferred treatment for patients with metastatic melanoma? Cancer Biother Radiopharm. 2012 Aug; 27(6):337-43. PMID: 22804456.
        View in: PubMed
      2. Dillman RO, Barth NM, VanderMolen L, Fong WH, Mahdavi KK, McClure SE. Should high-dose interleukin-2 still be the preferred treatment for patients with metastatic renal cell cancer? Cancer Biother Radiopharm. 2011 Jun; 26(3):273-7. PMID: 21711094.
        View in: PubMed
      3. Kim B, Dillman RO, Chen P, Hafer R, Cox C, Barth N, Carroll RM, VanderMolen L, Nguyen M, Huang J, Minion A, Plunkett M, Mackintosh R. A retrospective study of induction chemotherapy with docetaxel, cisplatinum, and 5-fluorouracil followed by concurrent radiotherapy with cetuximab in locally advanced head and neck cancer. Am J Otolaryngol. 2012 Jan-Feb; 33(1):93-7. PMID: 21524816.
        View in: PubMed
      4. Dillman RO, Barth NM, VanderMolen L, Allen K, Beutel LD, Chico S. High-dose chemotherapy and autologous stem cell rescue for metastatic breast cancer: superior survival for tandem compared with single transplants. Am J Clin Oncol. 2005 Jun; 28(3):281-8. PMID: 15923802.
        View in: PubMed
      5. Dillman R, Barth N, Vandermolen L, Mahdavi K, Beutel L, de Leon C, DePriest C, Nayak S. Autologous tumor cell line-derived vaccine for patient-specific treatment of advanced renal cell carcinoma. Cancer Biother Radiopharm. 2004 Oct; 19(5):570-80. PMID: 15650449.
        View in: PubMed
      6. Dillman RO, O'Connor AA, Simpson L, Barth NM, VanderMolen L, Vanderplas P. Does continuous-infusion interleukin-2 increase survival in metastatic melanoma? Am J Clin Oncol. 2003 Apr; 26(2):141-5. PMID: 12714884.
        View in: PubMed
      7. VanderMolen L, Sheehy PF, Dillman RO. Successful treatment of transitional cell carcinoma of the urethra with chemotherapy. Cancer Invest. 2002; 20(2):206-7. PMID: 11901541.
        View in: PubMed